Skip to content

Efficacy of a Novel Red light with Micro-needling Patch for Facial Skin Texture

Efficacy of a Novel Red light with Micro-needling Patch for Facial Skin Texture

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240722008
Enrollment
60
Registered
2024-07-22
Start date
2024-04-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with facial wrinkle wrinkle, Skin rejuvenation

Interventions

Smart minilux Combo ,Wavelength 630 +/- 10 nm ,Fluence 60 J/cm2 .,Microneedle patch consist of PMMA (Polymethylmethacrylate) ,Hieght 400 micrometers ,FDA Class I, IIA, IIB approved
Experimental Device,Experimental Device
Red LED light,Microneedle Patch

Sponsors

Bangkok Dusit Medical Services
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1.Participants female and male with age 25 to 55 years old with modified Fitzpatrick Wrinkle Scale more than class 1 2.Pre-menopause female

Exclusion criteria

Exclusion criteria: 1. Menopause 2. Current tobacco use 3. Tattoos that cover the proposed skin surface 4. Outdoor workers and sun exposure risk 5. Any skin lesions that might affect the study results such as atopic dermatitis ,herpes simplex infection, history of active or systemic infection, history of hypertrophic scar, eczema or sunburn in the area 6. Any history of adverse effects of polymethylmethacrylate (PMMA) 7. Have done Neuromodulators treatment (Botulinum toxins injections) within 6 months 8. Have done Filler injections in the nasolabial fold and periorbital within 1 year 9. Use of energy-based devices within 1 year 10. Have done Mesotherapy injections within 1 month 11. Have done Biostimulator injection within 6 months 12. Have done any sort of energy-based device within 1 year 13. Have done any sort of LASERs or skin resurface procedures within 1 months 14. Underlying with Photosensitivity condition including Porphyria, Lupus erythematosus, Rosacea, Solar urticaria 15. Underlying with bleeding diseases 16. Currently on Vitamin A derivatives, anticoagulants 17. Pregnant or on Lactation 18. Daily use anti-wrinkles facial cream and/or lotion

Design outcomes

Primary

MeasureTime frame
Skin rejuvination at 4 months after start of the intervention Modified Fitzpatrick Wrinkle Scale

Secondary

MeasureTime frame
Safety 2 week after every intervention Physician and Patient reported outcome using a questionnaire interview

Countries

Thailand

Contacts

Public ContactWatcharakorn Rattanakan

Thammasat university

pupae.pwr@gmail.com0831756576

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026